Allergic rhinitis

Drugs of Today

Volumn 37, Issue 5, 2001, Pages 283-309

  Reichmuth, D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; BECLOMETASONE; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; HISTAMINE H1 RECEPTOR ANTAGONIST; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCABASTINE; LORATADINE; MIZOLASTINE; MOMETASONE FUROATE; MONOCLONAL ANTIBODY; MONTELUKAST; OMALIZUMAB; OXYMETAZOLINE; RECOMBINANT ANTIBODY; TERFENADINE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC RHINITIS; ATOPY; DISEASE COURSE; DRUG INDUCED DISEASE; ENVIRONMENTAL FACTOR; HEALTH CARE COST; HEREDITY; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MORBIDITY; ONSET AGE; PREVALENCE; REVIEW; TH1 CELL; TH2 CELL;

EID: 0034934497     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2001.37.5.627951     Document Type: Review

References (155)

1. Allergic rhinitis update: Epidemiology and natural history
2. Prevalence and impact of multiple childhood chronic illnesses
3. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee
4. Present and potential therapy for allergic rhinitis
5. Consensus statement on the treatment of allergic rhinitis
6. Allergic rhinitis-update
7. Development of seasonal allergic rhinitis during the first 7 years of life
8. Epidemiology of asthma and allergic rhinitis in a total community, Tecumseh, Michigan
9. Natural history of hay fever: A 23-year follow-up of college students
10. Complications of allergic rhinitis
11. Mast cell-T cell interactions
12. Allergy and allergic diseases
13. Molecular pathology of allergic disease II: Upper airway disease
14. Therapeutic approaches to allergic rhinitis: Treating the child
15. Evidence for common genetic elements in allergic disease. Overview, epidemiology, and basic science of systemic allergic inflammation
16. Dense mapping of chromosome 12q13.12q23.3 and linkage to asthma and atopy
17. Effects of allergy season on mood and cognitive function
18. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires
19. Seasonal allergic rhinitis and antihistamine effects on children's learning
20. Learning impairment and allergic rhinitis
21. Is allergic rhinitis more frequent in young adults with extreme shyness? A preliminary survey
22. The role of allergy in sinusitis in children
23. The role of allergy in sinusitis in adults
24. The role of nasal airway obstruction in sinus disease and facial development
25. Antihistamine effects on actual driving performance in a standard test: A summary of Dutch experience, 1989-94
26. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance
27. Treatment of allergic rhinitis: Effects of allergic rhinitis and antihistamines on performance
28. Occupational injuries and medication use
29. Characterization of the rabbit detrusor response to histamine through pharmacologic antagonism
30. Adverse effects of medications on urinary symptoms and flow rate: A community-based study
31. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue
32. Epidemiology of seasonal perennial rhinitis: Clinical presentation and medical history
33. A comprehensive diagnostic approach to upper airway disease
34. Clinical findings in patients with allergic rhinitis
35. Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study
36. The association of allergen skin test reactivity and respiratory disease among whites in the US population: Data from the second National Health and Nutrition Examination Survey, 1976-1980
37. Quantitative IgE antibody assays in allergic diseases
38. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy
39. The relationship of respiratory allergy, skin test reactivity, and serum IgE in a community population sample
40. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass
41. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure
42. Local production of specific IgE antibodies in allergic rhinitis patients with negative skin tests
43. Quantitiation of inflammatory cells in the nasal mucosa of patients with allergic rhinitis and normal subjects
44. Nasal cytology in the diagnosis of allergic rhinitis in children
45. Nasal smear eosinophilia for the diagnosis of allergic rhinitis and eosinophilic non-allergic rhinitis
46. Quantitative cytology of nasal secretions with perennial allergic rhinitis in children: Comparison of noninfected and infected conditions
47. Quantitative cytology of nasal secretions under various conditions
48. Nasal cytology in rhinitis children: Comparison between brushing and blowing the nose
49. Eosinophil inflammation of the nasal mucosa in allergic and non-allergic rhinitis measured by eosinophil cationic protein levels in native nasal fluid and serum
50. High nitric oxide production in human paranasal sinuses
51. Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome
52. Exhaled nitric oxide in paediatric asthma and cystic fibrosis
53. Endogenous nitric oxide in allergic airway disease
54. Nasal nitric oxide is increased in patients with asthma and allergic rhinitis and may be modulated by nasal glucocorticoids
55. Increased levels of exhaled nitric oxide during nasal and oral breathing in subjects with seasonal rhinitis
56. Sinus disease in children with respiratory allergy
57. Computed tomographic study of the common cold
58. Computed tomographic study of the paranasal sinuses in allergic rhinitis
59. "Allergic sinusitis" revisited
60. Rhinopharyngoscopy, computed tomography and magnetic resonance imaging
61. How to proceed when you suspect rhinosinusitis
62. Rhinopharyngoscopy for the evaluation of allergic-immunologic disorders
63. Nasal endoscopy: Its role in office diagnosis
64. Assessment of nasal airway patency: A comparison of four methods
65. Evaluation of acoustic rhinometry in a nasal provocation test with allergen
66. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance
67. Nasal provocation
68. Nasal provocation test in the diagnostics of occupational allergic rhinitis
69. A review of the current guidelines for allergic rhinitis and asthma
70. Allergic rhinitis: The patient's perspective
71. The role of intervention in established allergy: Avoidance of indoor allergens in the treatment of chronic allergic disease
72. The biology of dust mites and the remediation of mite allergens in allergic disease
73. Reducing relative humidity is a practical way to control dust mites and their allergens in homes in temperate climates
74. Eradication of house dust mite from homes of atopic asthmatic sujects: A double-blind trial
75. The role and abatement of fungal allergens in allergic diseases
76. Environmental allergen avoidance: An overview
77. Cockroach allergens and asthma in Brazil: Identification of tropomysin as a major allergen with potential cross reactivity with mite and shrimp allergens
78. Ecology and elimination of cockroaches and allergens in the home
79. The role and remediation of animal allergens in allergic diseases
80. House dust mite control measures in the management of asthma: Meta-analysis
81. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
82. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis
83. Astelin® (azelastine hydrochloride) Nasal Spray, 137 mcg.
84. 1 receptor antagonists in allergic rhinitis: Systemic review of randomized controlled trials
85. Detection of suppression in children during treatment with intranasal beclomethasone dipropionate
86. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray
87. Systemic effects of intranasal steroids: An endocrinologist's perspective
88. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children
89. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids
90. Attained adult height after childhood asthma: Effect of glucocorticoid therapy
91. A meta-analysis of the effect of oral and inhaled corticosteroids on growth
92. Risk of cataract among users of intranasal corticosteroids
93. As-needed use of fluticasone propionate nasal spray reduced symptoms of seasonal allergic rhinitis
94. Leukotrienes in rhinitis
95. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: Placebo-controlled clinical trial
96. Therapy with cromolyn sodium
97. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination verus its components alone and placebo in the management of seasonal rhinitis
98. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray
99. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children
100. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for treatment of rhinorrhea in perennial rhinitis
101. Prophylactic inoculation against hay fever
102. Vaccination against hay fever: Report of results during the last three years
103. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: An analysis of randomized, prospective, single- or double-blind, placebo-controlled studies
104. Long-term clinical efficacy of grass pollen immunotherapy
105. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany
106. Efficacy of immunotherapy
107. Systemic reactions from allergen immunotherapy
108. Fatalities from immunotherapy (IT) and skin testing
109. WHO position paper, allergen immunotherapy: Therapeutic vaccines for allergic diseases
110. Sublingual versus injective immunotherapy in grass pollen allergic patients: A double blind (double dummy) study
111. Sublingual immunotherapy
112. Progress of medical science therapeutics: Application of immunologic principles to the management of hay fever, including a preliminary report on the use of Freund's adjuvant
113. Cutting edge: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
114. Immunostimulatory oligodeoxynucleotide induces Th1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice
115. Initial immunotherapy trial to explore the safety, tolerability and immunogenicity of subcutaneous injections of an AMB a1 immunostimulatory oligonucleotide conjugate [Aic] in ragweed allergic adults
116. Treatment of cat allergy with T-cell reactive peptides
117. Recombinant humanized mAb-E25, an anti-IgE mab, in birch pollen-induced seasonal allergic rhinitis
118. New directions in allergic diseases: Mechanism-based anti-inflammatory therapies
119. Hay fever, a post industrial revolution epidemic: A history of its growth during the 19th century
120. Increased prevalence of hay fever and atopy among children in Leipzig, East Germany
121. The environmental predictors of allergic disease
122. Effect of six-hour exposure to nitrogen dioxide on early-phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis
123. Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity
124. Childhood risk factors for atopy and the importance of early intervention
125. Relative scarcity of asthma and atopy among rural adolescents raised on a farm
126. Levels of environmental endotoxin and prevalence of atopic disease
127. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitization in infants at high risk of asthma
128. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood
129. Probiotics in primary prevention of atopic disease: A randomized placebo-controlled trial
130. Complementary foods and the development of food allergy
131. The development and prediction of atopy in high-risk children: Follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance
132. Epidemiology of physician-diagnosed allergic rhinitis in childhood
133. Genetic and environmental factors affecting the development of atopy through age 4 in children of atopic parents: A prospective randomized study of food allergen avoidance
134. Long-lasting sensitization to food during the first two years precedes allergic airway disease. The MAS Study Group, Germany
135. Allergen avoidance in infancy and allergy at 4 years of age
136. Atopy in childhood and diet in infancy. A nine-year follow-up study I. Clinical manifestations
137. Breastfeeding as prophylaxis against atopic disease: Prospective follow-up study until 17 years old
138. Parental smoking, breast feeding, and respiratory infection in development of allergic diseases
139. Relationship of diet in the development of atopy in infancy
140. Primary prevention of allergic sensitization: How might it work?
141. Reversing the trend: Reducing the prevalence of asthma
142. Controlled trials investigating the use of one partially hydrolyzed whey formula for dietary prevention of atopic manifestations until 60 months of age: An overview using meta-analytical techniques
143. Extensively and partially hydrolysed infant formulas for allergy prophylaxis
144. Hypoallergenic infant formulas
145. Pets, allergy and respiratory symptoms in children
146. Role of current and childhood exposure to cat and atopic sensitization
147. Exposure to pets and atopy-related diseases in the first 4 years of life
148. Immunotherapy in the prevention of allergic disease
149. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children
150. Immunotherapy reduces the risk of bronchial hyperreactivity in children with hayfever: The 2nd report from the preventative allergy treatment (PAT) study
151. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: First results of ETAC. Early Treatment of the Atopic Child
152. Prevention of asthma by ketotifen in infants with atopic dermatitis
153. Prevention of asthma with ketotifen in preasthmatic children: 3 Three-year follow-up study